Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 12/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 2/20 | 0.50 |
| ▸ | ACACA | Q13085 | 2/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107412 | 1.00 | F11 (0.55) | F11ATMKMT2AMEN1ACACB | |
| SCHEMBL2106583 | 0.90 | F11 (0.70) | F11ATMKMT2AMEN1ACACB | |
| SCHEMBL2106580 | 0.90 | F11 (0.70) | F11ATMKMT2AMEN1ACACB | |
| SCHEMBL13524383 | 0.85 | F11 (0.67) | F11ATMKMT2AMEN1 | |
| SCHEMBL13524378 | 0.84 | ATM (0.56) | F11ATMKMT2AMEN1 | |
| SCHEMBL3159727 | 0.84 | ATM (0.56) | F11ATMKMT2AMEN1 | |
| SCHEMBL3159697 | 0.84 | ATM (0.56) | F11ATMKMT2AMEN1 | |
| SCHEMBL3166877 | 0.84 | ATM (0.56) | F11ATMKMT2AMEN1 | |
| SCHEMBL3177393 | 0.84 | ATM (0.58) | F11ATMKMT2AMEN1ACACB | |
| SCHEMBL2329334 | 0.84 | F11 (0.69) | F11ATMKMT2AMEN1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | F11 2/4885ATM 1000/4885KMT2A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.